Melissa M. Taylor

Next Post

UNITY Biotechnology, Inc. Reports First Quarter 2022 Financial Results and Business Updates

Thu May 12 , 2022
Unity Biotechnology, Inc. -Completed enrollment in BEHOLD, the Phase 2 clinical trial of UBX1325 in DME; BEHOLD remains on track with 12-week safety and efficacy data anticipated by mid-year 2022- -Dosed first patient in ENVISION, the Phase 2 clinical trial of UBX1325 in wet age-related macular degeneration; ENVISION remains on […]